COMP <GO>
IOVA vs MRK // PIOTROSKI F-SCORE QUALITY
Iovance Biotherapeutics Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: IOVA 3
— MRK 11
▲ PIOTROSKI F-SCORE QUALITY LEADER: MRK
LAST: $8.48 (-11.30%) • MKT CAP: $4.33B
piotroski-score
4/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IOVA VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IOVA | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 34.30% | 74.80% | -40.50 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.76% | 3.42% | -11.18 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 60.60% | 1.30% | +59.30 | IOVA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.08 | 5.19 | +1.89 | IOVA | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.4 | 56.9 | -26.48 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.92 | +0.07 | IOVA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 18.4x | +14.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.33B | $361.02B | -$356.69B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IOVA REV | MRK REV | IOVA GROSS % | MRK GROSS % | IOVA FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $263.5M | $65.01B | 34.3% | 74.8% | -$336.2M | $12.36B |
| FY 2024 | $164.1M | $64.17B | 43.2% | 76.3% | -$364.0M | $18.10B |
| FY 2023 | $1.2M | $60.12B | 44.0% | 44.0% | -$361.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IOVA // BETA 0.99
MRK // BETA 0.92